Evidence map›Paper›PMID 37303025›Full record

ArticleAnnals of surgical oncology2023

Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.

Katie M Leick, Ann Tomanek-Chalkley, Kristen L Coleman, Carlos H F Chan

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Circulating tumour DNA - looking beyond the blood.Nature reviews. Clinical oncology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Katie M LeickDepartment of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Ann Tomanek-ChalkleyDepartment of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Kristen L ColemanHolden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Carlos H F ChanDepartment of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. carloshfchan@gmail.com.
University of Iowa Hospitals and Clinics · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Mark E Burkard · 2000 to 2026
$70.0M
NCI NIH HHS P30CA086862
6 · The paper itself

Abstract

backgroundRecurrence after curative-intent pancreatectomy for pancreatic ductal adenocarcinomas (PDAC) is quite frequent with locoregional and peritoneal recurrence in about one-third of cases. We hypothesize that peritoneal cell-free tumor DNA (ptDNA) present in the intraoperative peritoneal lavage (PL) fluid may be used as a predictive biomarker of locoregional and peritoneal recurrence. PATIENTS AND

methodsUnder institutional review board (IRB)-approved protocol, pre- and postresection PL fluids were collected from PDAC patients undergoing curative-intent pancreatectomy. PL fluids from PDAC patients with pathologically proven peritoneal metastasis were also collected as positive controls. Cell-free DNA was extracted from PL fluids. Droplet digital PCR (ddPCR) was performed using ddPCR KRAS G12/G13 screening kit. Recurrence-free survival (RFS) based on KRAS-mutant ptDNA level was determined using Kaplan-Meier methods.

resultsKRAS-mutant ptDNA was detected in PL fluids from all PDAC patients. KRAS-mutant ptDNA was detected in 11/21 (52%) preresection and 15/18 (83%) postresection PL fluid samples. With a median follow-up of 23.6 months, 12 patients developed recurrence (8 locoregional/peritoneal recurrence, 9 pulmonary/hepatic recurrence); 5/8 (63%) and 6/6 (100%) patients with mutant allele frequency (MAF) of > 0.10% in pre- and postresection PL fluids, respectively, developed recurrence. Using a cutoff value of 0.10% MAF, the presence of KRAS-mutant ptDNA in postresection PL fluid predicted a significantly shortened time to locoregional and peritoneal recurrence (median RFS of 8.9 months versus not reached, P = 0.003).

conclusionsThis study suggests that ptDNA in postresection PL fluids may be a useful biomarker to predict locoregional and peritoneal recurrence in resected PDAC patients.

Indexed as

Carcinoma, Pancreatic DuctalCirculating Tumor DNAPancreatic NeoplasmsPeritoneal NeoplasmsBiomarkers, TumorHumansMutationNeoplasm Recurrence, LocalPrognosisProto-Oncogene Proteins p21(ras)Biomarkers, TumorCirculating Tumor DNAProto-Oncogene Proteins p21(ras)Cell-free tumor DNADroplet digital PCRKRAS mutationMutant allele frequencyPancreatic cancerPeritoneal metastasis

Identifiers

PMID37303025
OpenAlexW4380208177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.